Conditions: Conjunctivitis Keratitis Blepharitis
Keywords: Blepharokeratoconjunctivitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 357
Healthy volunteers: no

Brief summary:
This study is to evaluate the safety and efficacy of loteprednol etabonate \[LE\] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (BKC).

Detailed description:

Arms:
arm 1: Loteprednol etabonate and tobramycin ophthalmic suspension arm 2: Tobramycin and dexamethasone ophthalmic suspension

Interventions: intervention 1: Loteprednol and tobramycin intervention 2: Tobramycin and dexamethasone
Intervention descriptions: intervention 1: Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days. intervention 2: Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.

Protocol document: